Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | CD19 CAR T-cells for adults

David L. Porter • 1 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia General Leukemia Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel

David L. Porter, MD, of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults for CD19 positive hematological malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David L. Porter

5:22
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David L. Porter • 1 Sep 2020
4:23
Impact of COVID-19 on CAR T-cell therapies
David L. Porter • 1 Sep 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals